Factors affecting the fibrillation of α-synuclein, a natively unfolded protein

Misbehaving Proteins: Protein (Mis)Folding, Aggregation, and Stability

Volumn , Issue , 2006, Pages 265-285

  Fink, Anthony L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84919871224     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-0-387-36063-8_12     Document Type: Chapter

References (89)

1. P. H. Weinreb, W. Zhen, A. W. Poon, K. A. Conway, and P. T. Lansbury, Jr., NACP, a protein implicated in Alzheimer's disease and learning, is natively unfolded, Biochemistry 35, 13709-13715 (1996).
2. V. N. Uversky, J. R. Gillespie, and A. L. Fink, Why are "natively unfolded" proteins unstructured under physiologic conditions? Proteins 41, 415-427 (2000).
3. J. Q. Trojanowski and V. M. Lee, Parkinson's disease and related alpha-synucleinopathies are brain amyloidoses, Ann. N. Y. Acad. Sci. 991, 107-110 (2003).
4. M. C. Irizarry, T. W. Kim, M. McNamara, R. E. Tanzi, J. M. George, D. F. Clayton, and B. T. Hyman, Characterization of the precursor protein of the non-A beta component of senile plaques (NACP) in the human central nervous system, J. Neuropathol. Exp. Neurol. 55, 889-895 (1996).
5. L. Maroteaux, J. T. Campanelli, and R. H. Scheller, Synuclein: a neuron-specific protein localized to the nucleus and presynaptic nerve terminal, J Neurosci 8, 2804-2815 (1988).
6. A. Iwai, E. Masliah, M. Yoshimoto, N. Ge, L. Flanagan, H. A. De Silva, A. Kittel, and T. Saitoh, The precursor protein of non-A beta component of Alzheimer's disease amyloid is a presynaptic protein of the central nervous system, Neuron 14, 467-475 (1995).
7. N. B. Cole, D. D. Murphy, T. Grider, S. Rueter, D. Brasaemle, and R. L. Nussbaum, Lipid droplet binding and oligomerization properties of the Parkinson's disease protein alpha-synuclein, J. Biol. Chem. 277, 6344-6352 (2002).
8. W. S. Davidson, A. Jonas, D. F. Clayton, and J. M. George, Stabilization of alpha-synuclein secondary structure upon binding to synthetic membranes, J. Biol. Chem. 273, 9443-9449 (1998).
9. E. Jo, J. McLaurin, C. M. Yip, P. George-Hyslop, and P. E. Fraser, alpha-Synuclein membrane interactions and lipid specificity, J. Biol. Chem 275, 34328-34334 (2000).
10. H. J. Lee, C. Choi, and S. J. Lee, Membrane-bound alpha-synuclein has a high aggregation propensity and the ability to seed the aggregation of the cytosolic form, J. Biol. Chem. 277, 671-678 (2002).
11. V. Narayanan and S. Scarlata, Membrane binding and self-association of alpha-synucleins, Biochemistry 40, 9927-9934 (2001).
12. M. Zhu and A. L. Fink, Lipid binding inhibits alpha-synuclein fibril formation, J. Biol. Chem. 278, 16873-16877 (2003).
13. M. Zhu, J. Li, and A. L. Fink, The association of alpha-synuclein with membranes affects bilayer structure, stability, and fibril formation, J. Biol. Chem. 278, 40186-40197 (2003).
14. C. M. Tanner, R. Ottman, S. M. Goldman, J. Ellenberg, P. Chan, R. Mayeux, and J. W. Langston, Parkinson disease in twins: an etiologic study, J. Am. Assoc. Med. 281, 341-346 (1999).
15. C. M. Tanner, The role of environmental toxins in the etiology of Parkinson's disease, Trends Neurosci. 12, 49-54 (1989).
16. M. Hashimoto, L. J. Hsu, Y. Xia, A. Takeda, A. Sisk, M. Sundsmo, and E. Masliah, Oxidative stress induces amyloid-like aggregate formation of NACP/alpha-synuclein in vitro, Neuroreport 10, 717-721 (1999).
17. C. Hertzman, M. Wiens, B. Snow, S. Kelly, and D. Calne, A case-control study of Parkinson's disease in a horticultural region of British Columbia, Mov. Disord. 9, 69-75 (1994).
18. E. C. Hirsch, J. P. Brandel, P. Galle, F. Javoy-Agid, and Y. Agid, Iron and aluminum increase in the substantia nigra of patients with Parkinson's disease: an X-ray microanalysis, J. Neurochem. 56, 446-451 (1991).
19. P. F. Good, C. W. Olanow, and D. P. Perl, Neuromelanin-containing neurons of the substantia nigra accumulate iron and aluminum in Parkinson's disease: a LAMMA study, Brain Res. 593, 343-346 (1992).
20. M. Yasui, T. Kihira, and K. Ota, Calcium, magnesium and aluminum concentrations in Parkinson's disease, Neurotoxicology 13, 593-600 (1992).
21. J. M. Gorell, B. A. Rybicki, J. C. Cole, and E. L. Peterson, E. L. Occupational metal exposures and the risk of Parkinson's disease, Neuroepidemiology 18, 303-308 (1999).
22. J. M. Gorell, C. C. Johnson, B. A. Rybicki, E. L. Peterson, G. X. Kortsha, G. G. Brown, and R. J. Richardson, Occupational exposure to manganese, copper, lead, iron, mercury and zinc and the risk of Parkinson's disease, Neurotoxicology 20, 239-247 (1999).
23. W. Hellenbrand, H. Boeing, B. P. Robra, A. Seidler, P. Vieregge, P. Nischan, J. Joerg, W. H. Oertel, E. Schneider, and G. Ulm, Diet and Parkinson's disease. II: A possible role for the past intake of specific nutrients. Results from a self-administered food-frequency questionnaire in a case-control study, Neurology 47, 644-650 (1996).
24. E. Altschuler, Aluminum-containing antacids as a cause of idiopathic Parkinson's disease, Med. Hypotheses 53, 22-23 (1999).
25. D. A. Butterfield and J. Kanski, Brain protein oxidation in age-related neurodegenerative disorders that are associated with aggregated proteins, Mech. Ageing Dev. 122, 945-962 (2001).
26. H. Ischiropoulos and J. S. Beckman, Oxidative stress and nitration in neurodegeneration: cause, effect, or association? J. Clin. Invest. 111, 163-169 (2003).
27. S. Kanda, J. F. Bishop, M. A. Eglitis, Y. Yang, and M. M. Mouradian, Enhanced vulnerability to oxidative stress by alpha-synuclein mutations and C-terminal truncation, Neuroscience 97, 279-284 (2000).
28. Y. Zhang, V. L. Dawson, and T. M. Dawson, Oxidative stress and genetics in the pathogenesis of Parkinson's disease, Neurobiol. Dis. 7, 240-250 (2000).
29. A. L. Fink, Protein aggregation: folding aggregates, inclusion bodies and amyloid, Folding & Design 3, 9-15 (1998).
30. V. N. Uversky, J. Li, and A. L. Fink, Evidence for a partially folded intermediate in alpha-synuclein fibril formation, J. Biol. Chem. 276, 10737-10744 (2001).
31. B. A. Rybicki, C. C. Johnson, J. Uman, and J. M. Gorell, Parkinson's disease mortality and the industrial use of heavy metals in Michigan, Mov. Disord. 8, 87-92 (1993).
32. J. M. Gorell, C. C. Johnson, B. A. Rybicki, E. L. Peterson, G. X. Kortsha, G. G. Brown, and R. J. Richardson, Occupational exposures to metals as risk factors for Parkinson's disease, Neurology 48, 650-658 (1997).
33. K. L. Kirkey, C. C. Johnson, B. A. Rybicki, E. L. Peterson, G. X. Kortsha, and J. M. Gorell, Occupational categories at risk for Parkinson's disease, Am. J. Ind. Med. 39, 564-571 (2001).
34. D. G. Le Couteur, A. J. McLean, M. C. Taylor, B. L. Woodham, and P. G. Board, Pesticides and Parkinson's disease, Biomed. Pharmacother. 53, 122-130 (1999).
35. V. N. Uversky, J. Li, M. Zhu, K. Bower, and A. L. Fink, Synergistic effects of pesticides and metals on the fibrillation of alpha-synuclein: Implications for Parkinson's disease, Neurotoxicology 23, 527-536 (2002).
36. V. N. Uversky, J. Li, and A. L. Fink, Metal-triggered structural transformations, aggregation, and fibrillation of human alpha-synuclein. A possible molecular link between Parkinson's disease and heavy metal exposure, J. Biol. Chem. 276, 44284-44296.
37. L. A. Munishkina, C. Phelan, V. N. Uversky, and A. L. Fink, Conformational behavior and aggregation of alpha-synuclein in organic solvents: modeling the effects of membranes, Biochemistry 42, 2720-2730 (2003).
38. K. A. Conway, J. D. Harper, and P. T. Lansbury, Accelerated in vitro fibril formation by a mutant a-synuclein linked to early-onset Parkinson disease, Nature Med. 4, 1318-1320 (1998).
39. V. N. Uversky, J. Li, and A. L. Fink, Pesticides directly accelerate the rate of alpha-synuclein fibril formation: a possible factor in Parkinson's disease, FEBS Lett. 500, 105-108 (2001).
40. J. A. Cohlberg, J. Li, V. N. Uversky, and A. L. Fink, Heparin and other glycosaminoglycans stimulate the formation of amyloid fibrils from alpha-synuclein in vitro, Biochemistry 41, 1502-1511 (2002).
41. J. Goers, V. N. Uversky, and A. L. Fink, Polycation-induced oligomerization and accelerated fibrillation of human alpha-synuclein in vitro, Prot. Sci. 12, 702-707 (2003).
42. V. N. Uversky, M. Cooper, K. S. Bower, J. Li, and A. L. Fink, Accelerated alpha-synuclein fibrillation in crowded milieu, FEBS Lett 515, 99-103 (2002).
43. V. N. Uversky, J. Li, and A. L. Fink, Trimethylamine-N-oxide-induced folding of alpha-synuclein, FEBS Lett. 509, 31-35 (2001).
44. V. N. Uversky, G. Yamin, P. O. Souillac, J. Goers, C. B. Glaser, and A. L. Fink, Methionine oxidation inhibits fibrillation of human alpha-synuclein in vitro, FEBS Lett. 517, 239-244 (2002).
45. V. N. Uversky, J. Li, P. O. Souillac, I. S. Millett, S. Doniach, R. Jakes, M. Goedert, and A. L. Fink, Biophysical properties of the synucleins and their propensities to fibrillate: inhibition of alphasynuclein assembly by beta- and gamma-synucleins, J. Biol. Chem. 277, 11970-11978 (2002).
46. J. Bradbury, Alpha-synuclein gene triplication discovered in Parkinson's disease, Lancet Neurol. 2, 715 (2003).
47. A. B. Singleton, M. Farrer, J. Johnson, A. Singleton, S. Hague, J. Kachergus, M. Hulihan, T. Peuralinna, A. Dutra, R. Nussbaum, S. Lincoln, A. Crawley, M. Hanson, D. Maraganore, C. Adler, M. R. Cookson, M. Muenter, M. Baptista, D. Miller, J. Blancato, J. Hardy, and K. Gwinn-Hardy, alpha-Synuclein locus triplication causes Parkinson's disease, Science 302, 841 (2003).
48. D. T. Dexter, P. Jenner, A. H. Schapira, and C. D. Marsden, Alterations in levels of iron, ferritin, and other trace metals in neurodegenerative diseases affecting the basal ganglia. The Royal Kings and Queens Parkinson's Disease Research Group, Ann. Neurol. 32 Suppl, S94-100 (1992).
49. G. C. Gazzaniga, B. Ferraro, M. Camerlingo, L. Casto, M. Viscardi, and A. Mamoli, A case control study of CSF copper, iron and manganese in Parkinson disease, Ital. J Neurol. Sci. 13, 239-243 (1992).
50. F. J. Jimenez-Jimenez, J. A. Molina, M. V. Aguilar, I. Meseguer, C. J. Mateos-Vega, M. J. Gonzalez-Munoz, F. De Bustos, A. Martinez-Salio, M. Orti-Pareja, M. Zurdo, and M. C. Martinez-Para, Cerebrospinal fluid levels of transition metals in patients with Parkinson's disease, J. Neural Transm. 105, 497-505 (1998).
51. E. Kienzl, L. Puchinger, K. Jellinger, W. Linert, H. Stachelberger, and R. F. Jameson, The role of transition metals in the pathogenesis of Parkinson's disease, J. Neurol. Sci. 134 Suppl, 69-78 (1995).
52. H. H. Liou, M. C. Tsai, C. J. Chen, J. S. Jeng, Y. C. Chang, S. Y. Chen, and R. C. Chen, Environmental risk factors and Parkinson's disease: a case-control study in Taiwan, Neurology 48, 1583-1588 (1997).
53. E. B. Montgomery, Jr., Heavy metals and the etiology of Parkinson's disease and other movement disorders, Toxicology 97, 3-9 (1995).
54. L. M. Sayre, G. Perry, C. S. Atwood, and M. A. Smith, The role of metals in neurodegenerative diseases, Cell Mol. Biol. 46, 731-741 (2000).
55. A. Seidler, W. Hellenbrand, B. P. Robra, P. Vieregge, P. Nischan, J. Joerg, W. H. Oertel, G. Ulm, and E. Schneider, Possible environmental, occupational, and other etiologic factors for Parkinson's disease: a case-control study in Germany, Neurology 46, 1275-1284 (1996).
56. L. S. Wechsler, H. Checkoway, G. M. Franklin, and L. G. Costa, A pilot study of occupational and environmental risk factors for Parkinson's disease, Neurotoxicology 12, 387-392 (1991).
57. A. H. Sadek, R. Rauch, and P. E. Schulz, (2003). Parkinsonism due to manganism in a welder, Int. J Toxicol. 22, 393-401 (2003).
58. N. Hakansson, P. Gustavsson, C. Johansen, and B. Floderus, Neurodegenerative diseases in welders and other workers exposed to high levels of magnetic fields, Epidemiology 14, 420-426 (2003).
59. G. Yamin, C. B. Glaser, V. N. Uversky, and A. L. Fink, Certain metals trigger fibrillation of methionine-oxidized α-synuclein, J. Biol. Chem. 278, 27630-27635 (2003).
60. L. A. Munishkina, J. Henriques, V. N. Uversky, and A. L. Fink, Role of protein-water interactions and electrostatics in alpha-synuclein fibril formation, Biochemistry 43, 3289-3300 (2004).
61. 2+ binding to alpha-synuclein regulates ligand binding and oligomerization, J. Biol. Chem. 276, 22680-22684 (2001).
62. R. Betarbet, T. B. Sherer, G. MacKenzie, M. Garcia-Osuna, A. V. Panov, and J. T. Greenamyre, Chronic systemic pesticide exposure reproduces features of Parkinson's disease, Nat. Neurosci. 3, 1301-1306 (2000).
63. B. I. Giasson and V. M. Lee, A new link between pesticides and Parkinson's disease, Nat. Neurosci. 3, 1227-1228 (2000).
64. T. B. Sherer, R. Betarbet, and J. T. Greenamyre, Pathogenesis of Parkinson's disease, Curr. Opin. Investig. Drugs 2, 657-662 (2001).
65. D. A. Di Monte, M. Lavasani, and A. B. Manning-Bog, Environmental factors in Parkinson's disease, Neurotoxicology 23, 487-502 (2002).
66. A. B. Manning-Bog, A. L. McCormack, J. Li, V. N. Uversky, A. L. Fink, and D. A. Di Monte, The herbicide paraquat causes up-regulation and aggregation of alpha-synuclein in mice, J. Biol. Chem. 277, 1641-1644 (2002).
67. A. D. Cardin and H. J. Weintraub, Molecular modeling of protein-glycosaminoglycan interactions, Arteriosclerosis 9, 21-32 (1989).
68. G. Perry, P. Richey, S. L. Siedlak, P. Galloway, M. Kawai, and P. Cras, Basic fibroblast growth factor binds to filamentous inclusions of neurodegenerative diseases, Brain Res. 579, 350-352 (1992).
69. M. D. Shtilerman, T. T. Ding, and P. T. Lansbury, Jr., Molecular crowding accelerates fibrillization of alpha-synuclein: could an increase in the cytoplasmic protein concentration induce Parkinson's disease? Biochemistry 41, 3855-3860 (2002).
70. L. A. Munishkina, E. M. Cooper, V. N. Uversky, and A. L. Fink, The effect of macromolecular crowding on protein aggregation and amyloid fibril formation, J. Mol. Recognit. 17, 456-464 (2004).
71. T. Antony, W. Hoyer, D. Cherny, G. Heim, T. M. Jovin, and V. Subramaniam, Cellular polyamines promote the aggregation of alpha-synuclein, J. Biol. Chem. 278, 3235-3240 (2003).
72. J. Goers, A. B. Manning-Bog, A. L. McCormack, I. S. Millett, S. Doniach, D. A. Di Monte, V. N. Uversky, and A. L. Fink, Nuclear localization of alpha-synuclein and its interaction with histones, Biochemistry 42, 8465-8471 (2003).
73. R. Sharon, M. S. Goldberg, I. Bar-Josef, R. A. Betensky, J. Shen, and D. J. Selkoe, Alpha-synuclein occurs in lipid-rich high molecular weight complexes, binds fatty acids, and shows homology to the fatty acid-binding proteins, Proc. Natl. Acad. Sci. USA 98, 9110-9115 (2001).
74. R. N. Cole and G. W. Hart, Cytosolic O-glycosylation is abundant in nerve terminals, J. Neurochem. 79, 1080-1089 (2001).
75. P. J. McLean, H. Kawamata, S. Ribich, and B. T. Hyman, Membrane association and protein conformation of alpha-synuclein in intact neurons. Effect of Parkinson's disease-linked mutations, J. Biol. Chem. 275, 8812-8816 (2000).
76. M. J. Volles and P. T. Lansbury, Jr., Vesicle permeabilization by protofibrillar alpha-synuclein is sensitive to Parkinson's disease-linked mutations and occurs by a pore-like mechanism, Biochemistry 41, 4595-4602 (2002).
77. M. Hashimoto, E. Rockenstein, M. Mante, M. Mallory, and E. Masliah, Beta-synuclein inhibits alpha-synuclein aggregation: a possible role as an anti-parkinsonian factor, Neuron 32, 213-223 (2001).
78. K. A. Conway, J. C. Rochet, R. M. Bieganski, and P. T. Lansbury, Jr., Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct, Science 294, 1346-1349 (2001).
79. J. Li, M. Zhu, A. B. Manning-Bog, D. A. Di Monte, and A. L. Fink, Dopamine and L-dopa disaggregate amyloid fibrils: implications for Parkinson's and Alzheimer's disease, FASEB J. 18, 962-964 (2004).
80. J. E. Duda, B. I. Giasson, Q. Chen, T. L. Gur, H. I. Hurtig, M. B. Stern, S. M. Gollomp, H. Ischiropoulos, V. M. Lee, and J. Q. Trojanowski, Widespread nitration of pathological inclusions in neurodegenerative synucleinopathies, Am. J. Pathol. 157, 1439-1445 (2000).
81. P. Jenner, D. T. Dexter, J. Sian, A. H. Schapira, and C. D. Marsden, Oxidative stress as a cause of nigral cell death in Parkinson's disease and incidental Lewy body disease, The Royal Kings and Queens Parkinson's Disease Research Group, Ann. Neurol. 32 Suppl, S82-S87 (1992).
82. W. Vogt, Oxidation of methionyl residues in proteins: tools, targets, and reversal, Free Radic. Biol. Med. 18, 93-105 (1995).
83. B. I. Giasson, J. E. Duda, I. V. Murray, Q. Chen, J. M. Souza, H. I. Hurtig, H. Ischiropoulos, J. Q. Trojanowski, and V. M. Lee, Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions, Science 290, 985-989 (2000).
84. E. H. Norris, B. I. Giasson, H. Ischiropoulos, and V. M. Lee, Effects of oxidative and nitrative challenges on alpha-synuclein fibrillogenesis involve distinct mechanisms of protein modifications, J. Biol. Chem. 278, 27230-27240 (2003).
85. E. Paxinou, Q. Chen, M. Weisse, B. I. Giasson, E. H. Norris, S. M. Rueter, J. Q. Trojanowski, V. M. Lee, and H. Ischiropoulos, Induction of alpha-synuclein aggregation by intracellular nitrative insult, J. Neurosci. 21, 8053-8061 (2001).
86. J. M. Souza, B. I. Giasson, Q. Chen, V. M. Lee, and H. Ischiropoulos, Dityrosine cross-linking promotes formation of stable alpha-synuclein polymers. Implication of nitrative and oxidative stress in the pathogenesis of neurodegenerative synucleinopathies, J. Biol. Chem. 275, 18344-18349 (2000).
87. G. Yamin, V. N. Uversky, and A. L. Fink, Nitration inhibits fibrillation of human alpha-synuclein in vitro by formation of soluble oligomers, FEBS Lett. 542, 147-152 (2003).
88. J. E. Duda, U. Shah, S. E. Arnold, V. M. Lee, and J. Q. Trojanowski, The expression of alpha-, beta-, and gamma-synucleins in olfactory mucosa from patients with and without neurodegenerative diseases, Exp. Neurol. 160, 515-522 (1999).
89. J. E. Galvin, T. M. Schuck, V. M. Lee, and J. Q. Trojanowski, Differential expression and distribution of alpha-, beta-, and gamma-synuclein in the developing human substantia nigra, Exp. Neurol. 168, 347-355 (2001).